Home > Resources > Company Profiles > Dyax Corporation

Dyax Corporation (DYAX)

EMAIL
PRINT
SHARE
TEXT SIZE:
SHARE
Send a copy to me

Separate multiple email addresses (max 20) with commas.

0/1500
Henry E. Blair , Founder/CEO/Chairman of the Board/Director/President
Industry: Healthcare
OPEN
LAST
$
PREV CLOSE
CHANGE
VOLUME


Overview
News
People
Financials

Company Information

Henry E. Blair, Founder/CEO/Chairman of the Board/Director/President

300 Technology Square

Cambridge, MA 02139

US Map it

Phone: (617) 225-2500

Fax: (617) 225-2501

www.dyax.com



Overview

A clinical stage biotechnology company focused on the discovery, development and commercialization of novel biotherapeutics for unmet medical needs, with an emphasis on oncology and inflammatory indications.

Employees

Number of Employees: 177
Revenue per Employee: $68,876

Top Executives

Dr. Ivana Magovcevic-Liebisch, Ph.D., J.D., Divisional Executive VP/General Counsel
George Migausky, CFO/Executive VP/Chief Accounting Officer
William Pullman, M.D., Ph.D., Executive VP/Other Executive Officer

Dr.Clive R. Wood, Ph.D., Divisional Executive VP/Chief Scientific Officer
Gustav A. Christensen, Executive VP/Other Executive Officer

Board of Directors

Financials

Quarterly
Annual

Income Statement 10/2008 08/2008 05/2008 03/2008
Sales NA -782 K. -712 K. -518 K.
Gross Operating Profit 5.49 Mil. 4.61 Mil. 3.36 Mil. 18.69 Mil.
Operating Income before D & A (EBITDA) -15.89 Mil. -18.63 Mil. -19.31 Mil. -1.05 Mil.
Total Income Before Interest Expenses (EBIT) -25.03 Mil. -23.12 Mil. -19.47 Mil. -818 K.
Total Net Income -26.64 Mil. -24.91 Mil. -21.34 Mil. -3.07 Mil.
Basic EPS, Total -0.43 -0.41 -0.35 -0.01
Diluted EPS, Total -0.43 -0.41 -0.35 -0.01

BALANCE STATEMENT 10/2008 08/2008 05/2008 03/2008
Cash and Equivalents 74.53 Mil. 38.59 Mil. 27.69 Mil. 29.36 Mil.
Total Assets NA 69.51 Mil. 60.35 Mil. 70.09 Mil.
Total Liabilities NA 48.67 Mil. 32.11 Mil. 16.98 Mil.
Total Capitalization -27.97 Mil. 14.96 Mil. 37.69 Mil. 59.51 Mil.

Cash Flow 10/2008 08/2008 05/2008 03/2008
Net Cash From Continuing Operations NA 7.77 Mil. 1.32 Mil. -40.22 Mil.
Net Cash From Investing Activities NA 5.06 Mil. 435 K. 35.3 Mil.
Net Cash From Financing Activities NA -3.53 Mil. -3.36 Mil. 22.92 Mil.
Net Change in Cash & Cash Equivalents NA 9.23 Mil. -1.67 Mil. 18.06 Mil.

powered by Interactive Data

Income Statement 2008 2007 2006 2005
Sales -2.2 Mil. -1.57 Mil. -2.61 Mil. -4.5 Mil.
Gross Operating Profit 28.3 Mil. 14.35 Mil. 22.47 Mil. 21.08 Mil.
Operating Income before D & A (EBITDA) -44.45 Mil. -37.85 Mil. -17 Mil. -22.39 Mil.
Total Income Before Interest Expenses (EBIT) -47.23 Mil. -46.52 Mil. -29.89 Mil. -32.09 Mil.
Total Net Income -56.31 Mil. -50.32 Mil. -30.94 Mil. -33.11 Mil.
Basic EPS, Total -1.06 -1.18 -0.87 -1.06
Diluted EPS, Total -1.06 -1.18 -0.87 -1.06

BALANCE STATEMENT 2008 2007 2006 2005
Cash and Equivalents 29.36 Mil. 11.3 Mil. 8.64 Mil. 6.98 Mil.
Total Assets 70.09 Mil. 63.76 Mil. 58.63 Mil. 63.56 Mil.
Total Liabilities 16.98 Mil. 17.4 Mil. 16.88 Mil. 16.73 Mil.
Total Capitalization 59.51 Mil. 63.67 Mil. 50.76 Mil. 58.48 Mil.

Cash Flow 2008 2007 2006 2005
Net Cash From Continuing Operations -40.22 Mil. -31.14 Mil. -18.29 Mil. -21.26 Mil.
Net Cash From Investing Activities 35.3 Mil. -23.4 Mil. -3.06 Mil. -53.16 Mil.
Net Cash From Financing Activities 22.92 Mil. 57.24 Mil. 23.08 Mil. 44.91 Mil.
Net Change in Cash & Cash Equivalents 18.06 Mil. 2.66 Mil. 1.66 Mil. -29.53 Mil.

powered by Interactive Data







Related Companies by Market Cap
Company Name
Price
Change
Market Cap
Emergent BioSolutions, Incorporated
212.12 Mil.
Nabi Pharmaceuticals
215.89 Mil.
Molecular Insight Pharmaceuticals, Incorporated
216.8 Mil.
Neurocrine Biosciences, Incorporated
202.14 Mil.

Company Profile Change Request

The data provided in our company profiles comes from third party information providers.

Also in Portfolio.com
Most Read
Most Emailed
Recently Commented